Last 139.00 GBp
Change Today 0.00 / 0.00%
Volume 5.4K
VEC On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 3:11 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

Open
139.00 GBp
Previous Close
139.00 GBp
Day High
139.75 GBp
Day Low
138.50 GBp
52 Week High
02/19/14 - 171.50 GBp
52 Week Low
07/23/13 - 82.25 GBp
Market Cap
558.3M
Average Volume 10 Days
403.2K
EPS TTM
-0.0069 GBp
Shares Outstanding
401.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc develops pharmaceutical therapies for the treatment of bronchopulmonary diseases. Its products target various diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company offers ADVATE, a serum-free recombinant factor VIII for haemophilia A; Adept, a 4% icodextrin solution used during surgery to reduce post-surgical adhesions; Extraneal, a solution containing icodextrin for peritoneal dialysis; and Seebri Breezhaler, a long-acting muscarinic antagonist for the treatment of COPD, as well as Asmasal Clickhaler, Asmabec Clickhaler, and Meptin for the treatment of asthma. Its product pipeline comprises QVA149, a fixed-dose combination of indacaterol maleate and glycopyrronium bromide for the treatment of adult patients with COPD; VR315 and VR632 that are inhaled combination therapies for asthma and COPD; VR506, an inhaled corticosteriod for the treatment of asthma; VR496, an inhaled, locally acting treatment for symptoms of inflammatory respiratory disease; and VR040, an inhaled, systemically acting form of apomorphine hydrochloride for treating off episodes associated with advanced Parkinson's disease. The company also provides various drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to allow aerosolized drug particles to achieve high lung deposition with low-dose variability; GyroHaler and OmniHaler, which are multi-unit dose DPI devices designed to deliver locally acting drugs to the lungs; Clickhaler, a single-dose inhaler; and Duohaler, a dry powder inhaler. It has development collaborations and license agreements with Novartis AG, Sandoz, Baxter International Inc, GlaxoSmithKline, and Tianjin KingYork Group Company Limited. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 521.0K GBP
Chief Operations Officer, President of US Ope...
Total Annual Compensation: 304.0K GBP
Compensation as of Fiscal Year 2013.

vectura group plc (VEC) Key Developments

Vectura Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Vectura announced earnings results for the second quarter and six months ended June 30, 2014. For the quarter, sales were SEK 35 million and EBITDA was SEK 22 million against sales of SEK 34 million and EBITDA of SEK 22 million a year ago. For the six months, sales were SEK 61 million and EBITDA was SEK 35 million against sales of SEK 54 million and EBITDA of SEK 27 million a year ago.

Vectura Group plc Announces US Collaboration Agreement for VR506

Vectura Group plc announced that it has signed a US collaboration, development and license agreement for VR506, Vectura's clinical stage asthma monotherapy delivered using Vectura's proprietary technology. The agreement for VR506 is with Vectura's existing, undisclosed, US partner for VR315 (a combination therapy for asthma/COPD). Under the terms of this agreement, Vectura's partner will be responsible for the commercialisation and manufacture of the product together with clinical development. Vectura will provide support for the US development of VR506, for which it will receive an initial payment of $4 million and up to $8 million upon achievement of pre-determined development milestones. Further development fees may be payable to Vectura if the program progresses beyond a pre-defined milestone. In addition, Vectura will receive a royalty from all VR506 US sales.

Vectura Group plc Presents at J.P. Morgan European Healthcare Conference, Jun-26-2014

Vectura Group plc Presents at J.P. Morgan European Healthcare Conference, Jun-26-2014 . Venue: London, United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 139.00 GBp 0.00

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Skyepharma PLC 258.00 GBp 0.00
View Industry Companies
 

Industry Analysis

VEC

Industry Average

Valuation VEC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.2x
Price/Book 2.5x
Price/Cash Flow 123.8x
TEV/Sales 15.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit www.vectura.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.